Lilly director receives stock award via deferral

ELI LILLY & Co director J Erik Fyrwald reported a compensation-related stock award rather than an open-market trade.

Rhea-AI Filing Summary

ELI LILLY & Co director J Erik Fyrwald reported a compensation-related stock award rather than an open-market trade. He acquired 10.78 shares of common stock at $919.90 per share through a grant classified as a “grant, award, or other acquisition.”

According to the footnote, he elected to defer cash compensation into stock units under the Lilly Directors' Deferral Plan, to be settled in shares after his separation from service. Following this grant, his direct holdings total 75,269.556 Lilly common shares.

Insider Trade Summary

Grant/Award: 10.78 shares

Grant/Award 1 txn

Insider Fyrwald J Erik

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	10.78	$919.90	$10K

Holdings After Transaction: Common Stock — 75,269.556 shares (Direct)

Footnotes (1)

1. F1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Key Figures

Stock award size: 10.78 shares Reference price per share: $919.90 per share Shares held after transaction: 75,269.556 shares

3 metrics

Stock award size 10.78 shares Common stock grant/award acquisition

Reference price per share $919.90 per share Value used for director stock award

Shares held after transaction 75,269.556 shares Direct Eli Lilly holdings after grant

Key Terms

grant, award, or other acquisition, Lilly Directors' Deferral Plan, stock units

3 terms

grant, award, or other acquisition financial

"transaction is coded as a grant, award, or other acquisition"

Lilly Directors' Deferral Plan financial

"stock units under the Lilly Directors' Deferral Plan and will be settled"

stock units financial

"deferred in lieu of cash compensation as stock units under the Lilly"

Stock units are individual pieces of ownership in a company, like slices of a pie that together make up the whole business. They matter to investors because each unit represents a claim on the company’s assets, profits and sometimes voting power, and changes in the number or value of these units affect ownership percentages, potential dividends and share dilution — all of which influence an investment’s worth.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Eli Lilly (LLY) director J Erik Fyrwald report in this Form 4?

Director J Erik Fyrwald reported receiving 10.78 Eli Lilly common shares as a stock award at $919.90 per share. The award is part of director compensation and not an open-market trade, and increased his direct holdings to 75,269.556 shares.

Was the Eli Lilly (LLY) transaction a stock purchase or a compensation grant?

The transaction was a compensation grant, coded as a grant, award, or other acquisition. Fyrwald elected to receive director compensation in stock units rather than cash, with settlement in Eli Lilly common shares after he leaves board service.

How many Eli Lilly (LLY) shares does J Erik Fyrwald hold after this transaction?

After the transaction, J Erik Fyrwald directly holds 75,269.556 Eli Lilly common shares. This total reflects his existing position plus the new 10.78-share stock award reported, giving context to the relatively small size of the latest compensation-related grant.

What price per share was used for J Erik Fyrwald’s Eli Lilly (LLY) stock award?

The grant used a reference price of $919.90 per Eli Lilly share for the 10.78-share award. This figure reflects how much cash compensation was converted into stock units under the company’s director deferral plan for this specific transaction.

How does the Lilly Directors' Deferral Plan affect this Eli Lilly (LLY) Form 4?

Under the Lilly Directors' Deferral Plan, Fyrwald chose to defer cash compensation into stock units, which will be settled in Eli Lilly common shares after his separation from service. The Form 4 records this deferral as an acquisition of 10.78 shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/21/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Fyrwald J Erik

(Last) (First) (Middle)

LILLY CORPORATE CENTER

(Street)

INDIANAPOLIS INDIANA 46285

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ELI LILLY & Co [ LLY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/20/2026		A		10.78(1)	A	$919.9	75,269.556	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. At the election of the reporting person, the shares acquired pursuant to this filing have been deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan and will be settled in shares of common stock following the reporting person's separation from service.

Remarks:

	/s/ Jonathan Groff for J. Erik Fyrwald, pursuant to authorization on file	04/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)